Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nordihydroguaiaretic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R known ✓ | P08069 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 9/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | FOS | P01100 | 2/20 | 1.00 |
| ▸ | TTR | P02766 | 2/20 | 1.00 |
| ▸ | JUN | P05412 | 2/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nordihydroguaiaretic Acid SCHEMBL13906133 | 1.00 | ALOX15 (1.00) | ALOX15ALOX12KDM4ERECQLHIF1A | |
| Nordihydroguaiaretic Acid SCHEMBL29434237 | 1.00 | ALOX15 (1.00) | ALOX15ALOX12KDM4ERECQLHIF1A | |
| Masoprocol SCHEMBL3818 | 1.00 | ALOX15 (1.00) | ALOX15ALOX12KDM4ERECQLHIF1A | |
| Nordihydroguaiaretic Acid SCHEMBL29434238 | 1.00 | ALOX15 (1.00) | ALOX15ALOX12KDM4ERECQLHIF1A | |
| Masoprocol SCHEMBL29355090 | 1.00 | ALOX15 (1.00) | ALOX15ALOX12KDM4ERECQLHIF1A | |
| Masoprocol SCHEMBL29350884 | 1.00 | ALOX15 (1.00) | ALOX15ALOX12KDM4ERECQLHIF1A | |
| Masoprocol SCHEMBL28156467 | 0.98 | ALOX15 (0.96) | ALOX15ALOX12KDM4ERECQLHIF1A | |
| SCHEMBL2227757 | 0.96 | ALOX15 (0.92) | ALOX15ALOX12KDM4ERECQLHIF1A | |
| Masoprocol SCHEMBL2304515 | 0.94 | ALOX15 (0.88) | ALOX15ALOX12KDM4ERECQLHIF1A | |
| Nordihydroguaiaretic Acid SCHEMBL28026820 | 0.94 | ALOX15 (0.88) | ALOX15ALOX12KDM4ERECQLHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727986-A1 | ABRASIVE ARTICLE | August Rüggeberg GmbH & Co. KG (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20250276107-A1 | HYDROGEL SYSTEMS AND METHODS FOR TREATING FISTULA AND OTHER INDICATIONS | TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION (US) | 2025-09-04 | — | — | US | claimed |
| EP-4011367-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-06-15 | — | — | EP | claimed |
| US-11142553-B2 | Protein composition, method for producing same and method for improving heat stability | SPIBER INC. (JP) | 2021-10-12 | — | — | US | claimed |
| US-20190352349-A1 | Protein Composition, Method for Producing Same and method for Improving Heat Stability | SPIBER INC. (JP) | 2019-11-21 | — | — | US | claimed |
| EP-3549946-A1 | PROTEIN COMPOSITION, METHOD FOR PRODUCING SAME AND METHOD FOR IMPROVING HEAT STABILITY | Spiber Inc. (JP) | 2019-10-09 | — | — | EP | claimed |
| US-20160354504-A1 | MALODOR COUNTERACTING COMPOSITIONS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2016-12-08 | — | — | US | claimed |
| EP-3101171-A1 | MALODOR COUNTERACTING COMPOSITIONS | International Flavors & Fragrances Inc. (US) | 2016-12-07 | — | — | EP | claimed |
| EP-2648528-B1 | COMPOSITION AND METHOD FOR IMPROVING STABILITY AND EXTENDING SHELF LIFE OF PROBIOTIC BACTERIA AND FOOD PRODUCTS THEREOF | DEGAMA BERRIER LTD (KY) | 2016-07-20 | — | — | EP | claimed |
| EP-1748767-A4 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS INC (US) | 2008-12-24 | — | — | EP | claimed |
| US-20020049349-A1 | Low monomer 1:1-monoadducts from hydroxy (meth) acrylates and diisocyanates and a process for their manufacture | DEGUSSA AG (DE) | 2002-04-25 | — | — | US | claimed |
| EP-1179555-A1 | 1:1 Monoadducts from hydroxy(meth)acrylates and diisocyanates having low monomer content and process for their preparation | Degussa AG (DE) | 2002-02-13 | — | — | EP | claimed |
| US-5859057-A | COMPRISING LINOLEIC ACID AND A ANTIOXIDANT PRESERVATIVE WHICH CREATES A NON-NOXIOUS VAPROUS PHEROMIC SUBSTANCE | SCHWARTZ ALAN M (US) | 1999-01-12 | — | — | US | claimed |
| US-5541232-A | CANCER THERAPY | CHEMEX PHARMACEUTICALS, INC. (US) | 1996-07-30 | — | — | US | claimed |
| WO-1995000129-A1 | TREATMENT OF MULTIDRUG RESISTANT DISEASES | CHEMEX PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | claimed |
| EP-0288534-B1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1991-12-18 | — | — | EP | claimed |
| US-5008294-A | Topical administration | CHEMEX PHARMACEUTICALS, INC. (US) | 1991-04-16 | — | — | US | claimed |
| EP-0396251-A2 | Use of fatty acids for the treatment of diseases associated with cytokines | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1990-11-07 | — | — | EP | claimed |
| WO-1988003806-A1 | PHARMACOLOGICALLY ACTIVE COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | claimed |
| WO-1988001509-A1 | PHARMACOLOGICALLY ACTIVE COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354504-A1 | MALODOR COUNTERACTING COMPOSITIONS | LPO, MAL2, ME1 | IGF1R 3521/4885ALOX15 125/4885ALOX12 117/4885 |
| US-20020049349-A1 | Low monomer 1:1-monoadducts from hydroxy (meth) acrylates and diisocyanates and a process for their manufacture | NOS1, PAM, ACP1 | IGF1R 1525/4885ALOX15 1122/4885ALOX12 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.